Business
DRI Healthcare Trust Announces Acquisition of Payment Streams based on the Cas9 Gene-Editing Technology for CASGEVY® (exagamglogene autotemcel)
DRI Healthcare Trust Announces Acquisition of Payment Streams based on the Cas9 Gene-Editing Tech...
About this update from Dri Healthcare Trust
[{"type":"text","content":"\n\n\n\n DRI Healthcare Trust Announces Acquisition of Payment Streams based on the Cas9 Gene-Editing Technology for CASGEVY® (exagamglogene autotemcel)\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n – Transaction adds another innovative rare disease therapy to the DHT portfolio –\n \n\n\n\n –\n \n\n Novel deal structure offers predictable annual cash flows as well as potential additional annual sales-based milestones and a one-time contingent payment –\n \n\n\n\n\n TORONTO\n \n\n ,\n \n\n Oct. 3, 2024\n \n\n /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the \"Trust\") today announced that a wholly owned subsidiary of the Trust has acquired a portion of Editas Medicine, Inc.'s (\"Editas\") payment rights under a non-exclusive license to Vertex Pharmaceuticals Incorporated (\"Vertex\") of Editas Medicine's Cas9 gene-editing technology for CASGEVY® (exagamglogene autotemcel) for an upfront purchase price of\n \n US$57 million\n \n .\n \n\n\n\n\n\n\n\n\n CASGEVY® is the first treatment approved by the U.S. Food and Drug Administration (\"FDA\") to utilize CRISPR technology.  CASGEVY® was approved by the FDA in\n \n December 2023\n \n for the treatment of sickle cell disease (\"SCD\") and in\n \n January 2024\n \n for the treatment of transfusion-dependent beta thalassemia (\"TDT\"), and by the European Medicines Agency for the treatment of both SCD and TDT in\n \n February 2024\n \n . CASGEVY® is the only approved gene-edited cell therapy for SCD and TDT. CASGEVY® is marketed worldwide by Vertex.\n \n\n SCD is an inherited blood disorder causing severe pain, organ damage, and shortened lifespan due to misshapen red blood cells. TDT is an inherited disorder that requires frequent blood transfusions to manage anemia that leads to symptoms such as fatigue, shortness of breath, and complications affecting various organs. Both SCD and TDT significantly impact quality of life and shorten life expectancy.\n \n\n The transacti...